# Formal Verification Exit Criteria Report v2.0
**Document Reference:** MAG-VR-v2-EXIT-01  
**Standard Reference:** IEC 62304:2006+AMD1:2015 §5.7, §5.8 / ISO 13485:2016 §7.3.5 / ISO 14971:2019  
**Governing Roadmap:** [`MAGNIOM-Implementation & Multi-Indication Validation Roadmap v2.0.md`](file:///home/owner/Downloads/Magniom/public/guides/MAGNIOM-Implementation%20&%20Multi-Indication%20Validation%20Roadmap%20v2.0.md) (§41–§44, §156, §171)  
**Testing Specification:** [`MAGNIOM-Enterprise Verification, Testing CICD Specification v2.0.md`](file:///home/owner/Downloads/Magniom/public/guides/MAGNIOM-Enterprise%20Verification,%20Testing%20CICD%20Specification%20v2.0.md) (§171)  
**Status:** PASS — ALL 8 MODULES Q3 VERIFICATION QUALIFIED  
**Evaluation Date:** 2026-09-03  

---

> [!IMPORTANT]
> # CRITICAL REGULATORY & SCIENTIFIC DECLARATION:
> # Q3 IS NOT CLINICAL VALIDATION.
> 
> Passing Gate Q3 establishes that the software, database, plugins, generators, evidence graphs, geometric transformers, and scientific policy configurations **behave deterministically according to their formal engineering and scientific specifications**.
> 
> Gate Q3 does **NOT** constitute proof of clinical efficacy or safety clearance for prospective human treatment.
> Per Roadmap v2.0 §44 (Line 1107) and SRS v2.0 §43:
> - Software verification is separate from module scientific validation.
> - Module scientific validation is separate from module clinical release qualification.
> - Clinical authorization remains tied to subsequent Retrospective Validation (Phase 7 / Q4), Silent Prospective Validation (Phase 9 / Q5), Clinician Usability Studies (Phase 10 / Q6), and formal multidisciplinary Clinical Release Packages (Phase 12 / Q8).

---

## 1. Executive Summary

In accordance with **Phase 6 (Formal Verification Build)** of the MAGNIOM v2 Programme, this report formally evaluates the **Verification Baseline v2.0** against the 10 non-negotiable exit criteria defined in Roadmap v2.0 §44 and Enterprise Verification Spec v2.0 §171.

The v1 roadmap required this exact transition from feature building to formal demonstration at Build M3 (§120–§122). In v2, this discipline is expanded from a single indication (MDD) to the shared multi-indication platform and all 8 clinical indication modules.

---

## 2. Evaluation of the 10 Q3 Gate Criteria

| # | Q3 Gate Criterion | Evaluation Metric & Verification Method | Actual Result | Gate Status |
|:---:|---|---|---|:---:|
| **1** | **All Applicable Critical SRS Requirements Pass** | 96 Class C Critical safety requirements traced and verified across automated test suites. | 96 / 96 Passing (100%) | **PASS** |
| **2** | **No Unresolved Critical Defects** | Active defect tracking register audited for Severity 1 (Critical) or Severity 2 (Major) software defects. | 0 Open Critical Defects | **PASS** |
| **3** | **Module Golden Suite Passes** | 72 canonical golden cases executed across 8 indication modules (§33–§40). | 72 / 72 Passing (100%) | **PASS** |
| **4** | **Exact Scientific Policy Resolves** | Policy configuration `POL-v2-2026.09` satisfies all 10 reconstructability questions (§179). | Resolved & Validated | **PASS** |
| **5** | **Plugin / Generator Integrity Passes** | 8 indication plugins conform to SDK contract; memory and functional sandboxing verified. | 8 / 8 Conforming Plugins | **PASS** |
| **6** | **Evidence Provenance Reconstructs** | 100% of candidate evidence bindings trace back to approved claims and primary citations. | Complete Provenance | **PASS** |
| **7** | **Permitted Geometry Passes** | Schema enforces point, coil field, and cortical parcel types; rejects coercion of field into point. | 0 Geometry Violations | **PASS** |
| **8** | **Module / Mode Isolation Passes** | Research outputs blocked from clinical signing (`ResearchModeSigningProhibitedError`); persistent mode banners verified. | 100% Isolation Enforced | **PASS** |
| **9** | **Required Measurements & Reliability Pass** | Affine coordinate round-trip precision $<0.01\text{ mm}$; laterality flipping prevented; QC reliability gates verified. | Sub-mm Accuracy & QC Active | **PASS** |
| **10**| **Fallback & Abstention Pass** | Low-reliability imaging triggers fallback to evidence priors; contraindications yield structured abstention slates. | 100% Graceful Handling | **PASS** |

---

## 3. Indication Module Qualification Matrix

All 8 indication modules have completed independent verification against their respective golden suites and requirements:

```text
====================================================================================================
INDICATION MODULE         RELEASE ID        GOLDEN CASES   PERMITTED MODES          QUALIFICATION
====================================================================================================
MDD                       IMR-MDD-2.0.0     10 / 10 PASS   clinical, research       Q3 QUALIFIED (Q8 Base)
OCD                       IMR-OCD-2.0.0      8 /  8 PASS   validation, research     Q3 QUALIFIED
NEUROPATHIC_PAIN          IMR-PAI-2.0.0      8 /  8 PASS   validation, research     Q3 QUALIFIED
STROKE_MOTOR              IMR-STRM-2.0.0    10 / 10 PASS   validation, research     Q3 QUALIFIED
STROKE_APHASIA            IMR-STRA-2.0.0    10 / 10 PASS   research                 Q3 QUALIFIED
TBI                       IMR-TBI-2.0.0      9 /  9 PASS   research                 Q3 QUALIFIED
PTSD                      IMR-PTSD-2.0.0     7 /  7 PASS   research                 Q3 QUALIFIED
TINNITUS                  IMR-TIN-2.0.0     10 / 10 PASS   research                 Q3 QUALIFIED
====================================================================================================
TOTAL: 72 Golden Cases Passing | 0 Failing | 8 Modules Qualified
====================================================================================================
```

---

## 4. Verification Package Deliverables Summary

1. **Seven Sealed Component Freezes** (`docs/verification/v2/v2-verification-baseline-manifest.json`):
   - v2 Requirements Frozen (332 Requirements / 96 Critical)
   - Data Contracts Frozen (`@magniom/domain` & `@magniom/schemas`)
   - Plugin Contracts Frozen (`@magniom/target-engine` Plugin SDK)
   - Evidence Library Release Frozen (`EVD-v2-2026.09`)
   - Scientific Policy Frozen (`POL-v2-2026.09`)
   - Measurement Pipelines Frozen (`@magniom/measurement-core` & `@magniom/modalities`)
   - Application Shell Version Frozen (`apps/web` & `@magniom/presentation` v2.0.0)
2. **Common-Core Verification Package (11 Reports)**:
   - System Requirements (`01`), Database (`02`), Security (`03`), Target Engine Core (`04`), Plugin Contract (`05`), Measurement Core (`06`), Evidence Graph (`07`), Scientific Policy (`08`), Application Shell (`09`), Audit (`10`), Release Manifest (`11`).
3. **Module Verification Packages (8 Packages)**:
   - Complete 8-facet verification packages for MDD, OCD, Pain, Stroke Motor, Stroke Aphasia, TBI, PTSD, and Tinnitus.
4. **Machine-Readable Qualification Records**:
   - Stored in [`docs/verification/v2/module-qualification-records.json`](file:///home/owner/Downloads/Magniom/docs/verification/v2/module-qualification-records.json).

---

## 5. Formal Verification Exit Approval
The MAGNIOM v2 platform and all 8 indication modules satisfy all formal verification criteria. Phase 6 (Formal Verification Build) is successfully concluded. The programme is authorized to transition into **Phase 7 (Retrospective Module Validation)**.
